Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs.

Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C.

Rheumatology (Oxford). 2000 Sep;39(9):975-81.

PMID:
10986302
2.

A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.

Choy EH, Smith C, Doré CJ, Scott DL.

Rheumatology (Oxford). 2005 Nov;44(11):1414-21. Epub 2005 Jul 19. Review.

PMID:
16030080
3.

Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.

Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM.

Clin Ther. 2008 Nov;30(11):1939-55. doi: 10.1016/j.clinthera.2008.11.007. Review.

PMID:
19108784
4.

Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis.

Katchamart W, Trudeau J, Phumethum V, Bombardier C.

Cochrane Database Syst Rev. 2010 Apr 14;(4):CD008495. doi: 10.1002/14651858.CD008495. Review.

PMID:
20393970
5.

Methotrexate in rheumatoid arthritis.

Swierkot J, Szechiński J.

Pharmacol Rep. 2006 Jul-Aug;58(4):473-92. Review.

6.

Disease-modifying antirheumatic drugs: gold, penicillamine, antimalarials, and sulfasalazine.

McConkey B.

Curr Opin Rheumatol. 1991 Jun;3(3):348-54. Review.

PMID:
1679342
7.

Disease-modifying antirheumatic drugs. Potential effects in older patients.

Gardner G, Furst DE.

Drugs Aging. 1995 Dec;7(6):420-37. Review.

PMID:
8601050
8.

Leflunomide for treating rheumatoid arthritis.

Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, Wells G.

Cochrane Database Syst Rev. 2003;(1):CD002047. Review.

PMID:
12535423
9.

Rational use of new and existing disease-modifying agents in rheumatoid arthritis.

Kremer JM.

Ann Intern Med. 2001 Apr 17;134(8):695-706. Review.

PMID:
11304108
10.

Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.

Farahani P, Levine M, Gaebel K, Thabane L.

Can J Clin Pharmacol. 2005 Fall;12(3):e254-63. Epub 2005 Nov 7. Review.

PMID:
16278497
11.

Disease-modifying antirheumatic drugs, including methotrexate, gold, antimalarials, and D-penicillamine.

Conaghan PG, Brooks P.

Curr Opin Rheumatol. 1995 May;7(3):167-73. Review.

PMID:
7612407
12.

Disease-modifying antirheumatic drugs.

Conaghan PG, Lehmann T, Brooks P.

Curr Opin Rheumatol. 1997 May;9(3):183-90. Review.

PMID:
9204252
13.

Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review.

Whittle SL, Hughes RA.

Rheumatology (Oxford). 2004 Mar;43(3):267-71. Epub 2004 Jan 6. Review.

PMID:
14963199
14.

Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis.

Garrood T, Scott DL.

BioDrugs. 2001;15(8):543-61. Review.

PMID:
11543695
15.

The role of anti-malarials in rheumatoid arthritis--the American experience.

Khraishi MM, Singh G.

Lupus. 1996 Jun;5 Suppl 1:S41-4. Review.

PMID:
8803910
16.

Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.

Doyle MK, Rahman MU, Han C, Han J, Giles J, Bingham CO 3rd, Bathon J.

Semin Arthritis Rheum. 2009 Oct;39(2):123-31. doi: 10.1016/j.semarthrit.2008.08.002. Epub 2008 Sep 27. Review.

PMID:
18823645
17.

Combining sulphasalazine and methotrexate in rheumatoid arthritis: early clinical impressions.

Haagsma CJ, van Riel PL, van de Putte LB.

Br J Rheumatol. 1995 Nov;34 Suppl 2:104-8. Review.

PMID:
8535640
18.

Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.

Roubille C, Haraoui B.

Semin Arthritis Rheum. 2014 Apr;43(5):613-26. doi: 10.1016/j.semarthrit.2013.09.005. Epub 2013 Oct 5. Review.

PMID:
24231065
19.

[The goal for the treatment of rheumatoid arthritis should be remission].

Möttönen T, Mäkinen H, Puolakka K.

Duodecim. 2010;126(12):1457-64. Review. Finnish.

PMID:
20617749
20.

[Disease-modifying drugs in rheumatoid arthritis. Duration of treatment and reasons for withdrawal].

Grefslie H, Kvien TK, Toverud EL.

Tidsskr Nor Laegeforen. 1996 Mar 20;116(8):958-62. Review. Norwegian.

PMID:
8650656

Supplemental Content

Support Center